Skip to Main Content

Author Details

Volker Endris
Institute of Pathology, University Hospital Heidelberg
2001
132
42
PMIDPaper TitleJournal TitlePublished Year
36562826BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.Cancer Immunol Immunother2023
37327584Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).Transl Oncol2023
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
35430765Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.Genes Chromosomes Cancer2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
34325986Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Urol Oncol2022
33455880ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.Ann Oncol2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34521064Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary.Eur J Cancer2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34605937Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie.Pathologe2021
33938987[Variant interpretation in molecular pathology and oncology : An introduction].Pathologe2021
33964449Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.J Mol Diagn2021
34206061Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance.J Clin Med2021
34173019Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing.Virchows Arch2021
34112699Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.Cancer Discov2021
34164264Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.Transl Lung Cancer Res2021
32319699NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.Genes Chromosomes Cancer2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
31926173Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.Gastroenterology2020
31925805Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.Hepatology2020
32017710Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.J Clin Invest2020
31652375Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.Genes Chromosomes Cancer2020
33115416The majority of β-catenin mutations in colorectal cancer is homozygous.BMC Cancer2020
33161228Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.EBioMedicine2020
33243186Correction to: The majority of β-catenin mutations in colorectal cancer is homozygous.BMC Cancer2020
32119917Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.J Thorac Oncol2020
32280037High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.Urol Oncol2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
32143116Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.Lung Cancer2020
30615206Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.Hepatology2019
31753813Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer.Cold Spring Harb Mol Case Stud2019
30238975Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.Int J Cancer2019
30255938Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma.Int J Cancer2019
30230086Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.Genes Chromosomes Cancer2019
31491926RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.Cancers (Basel)2019
31349062Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.J Thorac Oncol2019
31549213The BRCA2 mutation status shapes the immune phenotype of prostate cancer.Cancer Immunol Immunother2019
31620244Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing.Oncotarget2019
30737205Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.Clin Chem2019
31008532Variant classification in precision oncology.Int J Cancer2019
31089797[From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]Pathologe2019
30963573Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.Int J Cancer2019
30901310<i>RSPO2</i> gene rearrangement: a powerful driver of β-catenin activation in liver tumours.Gut2019
30350867Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.Int J Cancer2019
30653256Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.Int J Cancer2019
30669647Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.Cancers (Basel)2019
30446996Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.Int J Cancer2019
29044880Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.Genes Chromosomes Cancer2018
  • 1 - 50 of 132

Recommended Authors

Job van Riet
Erasmus MC Cancer Institute
Career Start Year 2017
Number of shared co-authors 0
Jason D Peterson
Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center
Career Start Year 2014
Number of shared co-authors 0
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
David A Moore
University College London Cancer Institute
Career Start Year 2012
Number of shared co-authors 4
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 2
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 3
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 5
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 5
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 4
Dmitriy Sonkin
National Cancer Institute
Career Start Year 2008
Number of shared co-authors 5
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 7
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 10
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 2
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 6
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 0
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 13
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 6
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 2
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 3
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Career Start Year 1999
Number of shared co-authors 2
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 1
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 12
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 4
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 7
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 12

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 100
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 66
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 39
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 38
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 33
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 26
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 25
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 22
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 19
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 16
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 13
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 9
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 8
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 8
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 8
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 7
Barbara Hutter
National Center for Tumor Diseases (NCT) Heidelberg
Co-authored papers 7
Matthias Schlesner
University of Augsburg
Co-authored papers 5
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 5
Christof von Kalle
Berlin Institute of Health at Charite-Universitatsmedizin Berlin
Co-authored papers 5
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 4
Stephanie Roessler
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Michael Bockmayr
Institute of Pathology, Charite Universitatsmedizin Berlin
Co-authored papers 4
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 4
Andreas von Deimling
Co-authored papers 3
Stephan Wolf
Co-authored papers 3
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 3
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Tomasz Zemojtel
Berlin Institute of Health (BIH)
Co-authored papers 3
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 3
Release 1.2